Targeting pheochromocytoma/paraganglioma with polyamine inhibitors - Archive ouverte HAL Accéder directement au contenu
Article Dans Une Revue Metabolism Année : 2020

Targeting pheochromocytoma/paraganglioma with polyamine inhibitors

Fernando Bril
  • Fonction : Auteur
Yiling Xu
  • Fonction : Auteur
Laura Shelton
  • Fonction : Auteur
Srilaxmi Kalavalapalli
  • Fonction : Auteur
Arielle Click
  • Fonction : Auteur
Douglas Lee
  • Fonction : Auteur
Chris Beecher
  • Fonction : Auteur
Austin Kirby
  • Fonction : Auteur
Kimi Kong
  • Fonction : Auteur
Jose Trevino
  • Fonction : Auteur
Abhishek Jha
Shashank Jatav
  • Fonction : Auteur
Kriti Kriti
  • Fonction : Auteur
Soumya Luthra
  • Fonction : Auteur
Timothy Garrett
Joy Guingab-Cagmat
  • Fonction : Auteur
Daniel Plant
  • Fonction : Auteur
Prodip Bose
  • Fonction : Auteur
Kenneth Cusi
  • Fonction : Auteur
  • PersonId : 887330
Robert Hromas
  • Fonction : Auteur
Arthur Tischler
  • Fonction : Auteur
James Powers
  • Fonction : Auteur
Priyanka Gupta
  • Fonction : Auteur
James Bibb
  • Fonction : Auteur
Felix Beuschlein
Mercedes Robledo
  • Fonction : Auteur
  • PersonId : 958839
Bruna Calsina
  • Fonction : Auteur
Henri Timmers
  • Fonction : Auteur
Matthias Kroiss
Susan Richter
  • Fonction : Auteur
Katharina Langton
Graeme Eisenhofer
Hans Ghayee

Résumé

Background: (PCCs) and paragangliomas (PGLs) are neuroendocrine tumors that are mostly benign. Metastatic disease does occur in about 10% of cases of PCC and up to 25% of PGL, and for these patients no effective therapies are available. Patients with mutations in the succinate dehydrogenase subunit B (SDHB) gene tend to have metastatic disease. We hypothesized that a down-regulation in the active succinate dehydrogenase B subunit should result in notable changes in cellular metabolic profile and could present a vulnerability point for successful pharmacological targeting. Methods: Metabolomic analysis was performed on human hPheo1 cells and shRNA SDHB knockdown hPheo1 (hPheo1 SDHB KD) cells. Additional analysis of 115 human fresh frozen samples was conducted. In vitro studies using N1,N11-diethylnorspermine (DENSPM) and N1,N12- diethylspermine (DESPM) treatments were carried out. DENSPM efficacy was assessed in human cell line derived mouse xenografts. Results: Components of the polyamine pathway were elevated in hPheo1 SDHB KD cells compared to wild-type cells. A similar observation was noted in SDHx PCC/PGLs tissues compared to their non-mutated counterparts. Specifically, spermidine, and spermine were significantly elevated in SDHx-mutated PCC/PGLs, with a similar trend in hPheo1 SDHB KD cells. Polyamine pathway inhibitors DENSPM and DESPM effectively inhibited growth of hPheo1 cells in vitro as well in mouse xenografts. Conclusions: This study demonstrates overactive polyamine pathway in PCC/PGL with SDHB mutations. Treatment with polyamine pathway inhibitors significantly inhibited hPheo1 cell growth and led to growth suppression in xenograft mice treated with DENSPM. These studies strongly implicate the polyamine pathway in PCC/PGL pathophysiology and provide new foundation for exploring the role for polyamine analogue inhibitors in treating metastatic PCC/PGL.
Fichier principal
Vignette du fichier
Metabolism2020RaiSK.pdf (2.01 Mo) Télécharger le fichier
Origine Fichiers produits par l'(les) auteur(s)
Loading...

Dates et versions

hal-02890700 , version 1 (06-07-2020)

Identifiants

Citer

Sudhir Kumar Rai, Fernando Bril, Heather Hatch, Yiling Xu, Laura Shelton, et al.. Targeting pheochromocytoma/paraganglioma with polyamine inhibitors. Metabolism, 2020, 110, pp.154297. ⟨10.1016/j.metabol.2020.154297⟩. ⟨hal-02890700⟩
69 Consultations
358 Téléchargements

Altmetric

Partager

Gmail Mastodon Facebook X LinkedIn More